LENZ Therapeutics (LENZ) Accounts Payables (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Accounts Payables data on file, last reported at $10.9 million in Q1 2026.

• Quarterly Accounts Payables rose 198.52% year-over-year to $10.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.9 million (up 198.52% YoY) and the FY2025 annual result came in at $4.2 million, down 2.11% from the prior year.
• Accounts Payables rose to $10.9 million in Q1 2026 per LENZ's latest filing, from $4.2 million in the prior quarter.
• Across five years, Accounts Payables topped out at $10.9 million in Q1 2026 and bottomed at $2.0 million in Q1 2023.
• The 5-year median for Accounts Payables is $3.8 million (2023), against an average of $4.2 million.
• The widest annual swing landed in 2024, when Accounts Payables surged 257.98%; it then tumbled 48.66% in 2025.
• Tracing LENZ's Accounts Payables over 5 years: stood at $2.6 million in 2022, then jumped by 118.98% to $5.7 million in 2023, then fell by 25.46% to $4.3 million in 2024, then declined by 2.11% to $4.2 million in 2025, then soared by 162.28% to $10.9 million in 2026.
• Per Business Quant, the three latest LENZ Accounts Payables figures stand at $10.9 million (Q1 2026), $4.2 million (Q4 2025), and $4.3 million (Q3 2025).

Peer Comparison